Clinical Efficacy of Radical Resection of Intrahepatic Cholangiocarcinoma Combined with Apatinib in the Treatment of Intrahepatic Cholangiocarcinama
Objective To investigate the therapeutic effect and safety of radical tumor resection combined with apatinib in patients with intrahepatic cholangiocarcinoma.Methods Patients with intrahepatic cholangiocarcinoma admitted to the Third People's Hospital of Shangqiu from December 1,2017 to February 1,2020 were selected as study subjects,and patients were divided into experimental group(surgery combined with apatinib treatment)and control group(surgery treatment)according to whether they received molecular targeted drug therapy or not.By comparing and analyzing the overall survival rate after surgery,tumor recurrence/metastasis rate and the blood routine and liver function levels during the follow-up period of patients in both groups,the therapeutic effects and safety of radical tumor resection combined with apatinib for patients with intrahepatic cholangiocarcinoma were clarified.Results There were no significant differences in general data such as blood routine,liver function,tumor markers and tumor differentiation between the two groups(P＞0.05).6 months after surgery,the levels of aspartate aminotransferase,alpha-fetoprotein,carbohydrate antigen 19-9 and carcinoembryonic antigen in experimental group were lower than those in control group(P＜0.05).The postoperative recurrence/metastasis rate of experimental group was lower than that of control group(P=0.028).In terms of adverse reactions,only 2 patients in the experimental group had diarrhea(4.44％),1 patient had vomiting(2.22％),and 2 patients had fatigue(4.44％).The incidence of adverse reactions related to various drugs was low.Follow-up observation showed no significant difference in overall survival rate between the two groups(P＞0.05).Conclusion Apatinib therapy in patients with intrahepatic cholangiocarcinoma after radical tumor resection can delay tumor recurrence/metastasis to a certain extent and is well tolerated in patients.
万方数据
维普
